| Review of meningococcal group B vaccines. | |
| | |
MedLine Citation:
|
PMID: 20144017 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
No broadly effective vaccines are available for prevention of group B meningococcal disease, which accounts for >50% of all cases. The group B capsule is an autoantigen and is not a suitable vaccine target. Outer-membrane vesicle vaccines appear to be safe and effective, but serum bactericidal responses in infants are specific for a porin protein, PorA, which is antigenically variable. To broaden protection, outer-membrane vesicle vaccines have been prepared from >1 strain, from mutants with >1 PorA, or from mutants with genetically detoxified endotoxin and overexpressed desirable antigens, such as factor H binding protein. Also, recombinant protein vaccines such as factor H binding protein, given alone or in combination with other antigens, are in late-stage clinical development and may be effective against the majority of group B strains. Thus, the prospects have never been better for developing vaccines for prevention of meningococcal disease, including that caused by group B strains. |
| | |
Authors:
|
Dan M Granoff |
Related Documents
:
|
10838647 - Safety, immunogenicity, and induction of immunologic memory by a serogroup c meningococ... 12160167 - The effect of subcapsular meningococcal b + c vaccine on the prognosis of patients with... 16458277 - Synthesis of octa- and dodecamers of d-ribitol-1-phosphate and their protein conjugates. 9203657 - Preclinical evaluation of a novel group b meningococcal conjugate vaccine that elicits ... 7130967 - Immunogenicity in chimpanzees of experimental hepatitis b vaccines prepared from intact... 20124097 - A novel hla (hla-a*0201) transgenic rabbit model for preclinical evaluation of human cd... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Volume: 50 Suppl 2 ISSN: 1537-6591 ISO Abbreviation: Clin. Infect. Dis. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-10 Completed Date: 2010-04-30 Revised Date: 2011-07-25 |
Medline Journal Info:
|
Nlm Unique ID: 9203213 Medline TA: Clin Infect Dis Country: United States |
Other Details:
|
Languages: eng Pagination: S54-65 Citation Subset: IM |
Affiliation:
|
Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, California, USA. dgranoff@chori.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antigens, Bacterial
/
immunology Bacterial Proteins / immunology Biomedical Research / trends Endotoxins / immunology Humans Meningitis, Meningococcal / epidemiology*, microbiology, prevention & control* Meningococcal Vaccines / immunology* Neisseria meningitidis, Serogroup B / immunology* Porins / immunology Secretory Vesicles / immunology |
| Grant Support | |
ID/Acronym/Agency:
|
C06 RR-16226/RR/NCRR NIH HHS; M01 RR001271-230443/RR/NCRR NIH HHS; M01 RR001271-240443/RR/NCRR NIH HHS; R01 AI046464/AI/NIAID NIH HHS; R01 AI046464-07/AI/NIAID NIH HHS; R01 AI046464-08A1/AI/NIAID NIH HHS; R21 AI061533-02/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, Bacterial; 0/Bacterial Proteins; 0/Endotoxins; 0/Meningococcal Vaccines; 0/Porins; 0/factor H-binding protein, Neisseria meningitidis; 0/porin protein, Neisseria |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines.
Next Document: Combined interventions may improve success when treating sudden cardiac arrest.